초록 ▼

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e., no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location).

대표청구항 ▼

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or

The invention features devices and methods for the systemic delivery of fentanyl or a fentanyl congener (e.g., sufentanil) to treat pain. In the present invention, a drug formulation comprising fentanyl or a fentanyl congener is stored within a drug delivery device (e.g., contained in a reservoir or impregnated within a matrix within the controlled drug delivery device). The drug formulation comprises an amount of drug sufficient for treatment and is stable at body temperatures (i.e., no unacceptable degradation) for the entire pre-selected treatment period. The drug delivery devices store the drug formulation safely (e.g., without dose dumping), provide sufficient protection from bodily processes to prevent unacceptable degradation of the formulation, and release the drug formulation in a controlled fashion at a therapeutically effective rate to treat pain. In use, the drug delivery device is implanted in the subject's body at an implantation site, and the drug formulation is released from the drug delivery device to a delivery site. The delivery site may be the same as, near, or distant from the implantation site. Once released at the delivery site, the drug formulation enters the systemic circulation and is transported to the site of action in the body to modulate the pain response (e.g., the brain or other pain sensory location). ch R represents C16-C22alkyl radicals, taken as a mixture or separately, and M is an alkali metal; quaternary ammonium salts, fatty amines and their salts; and mixtures thereof. 12. The nanoemulsion of claim 10, wherein the amount of ionic amphiphilic lipid(s) is 0.01 to 5% by weight with respect to the total weight of the nanoemulsion. 13. The nanoemulsion of claim 1, further comprising an additive which improves the transparency thereof and selected from the group consisting lower alcohols, glycols, sugars and mixtures thereof. 14. The nanoemulsion of claim 13, wherein the additive is present in a concentration ranging from 5 to 20% by weight with respect to the total weight of the nanoemulsion. 15. The nanoemulsion of claim 1, further comprising a cosmetic, dermatological or ophthalmological active agent. 16. A composition suitable for topical use comprising the nanoemulsion of claim 1. 17. An ophthalmic vehicle comprising the nanoemulsion of claim 1. 18. A method of caring for, treating and/or making up the skin, face and/or scalp, comprising applying the nanoemulsion of claim 1 to the skin, face and/or scalp. 19. A method of caring for and/or treating the hair, comprising applying the nanoemulsion of claim 1 to the hair. 20. A method of caring for and/or moisturizing the skin, mucous membranes and/or scalp, comprising applying the nanoemulsion of claim 1 to the skin, mucous membranes and/or scalp. 21. A method of preparing the nanoemulsion of claim 1, comprising: mixing the aqueous phase and the oily phase with vigorous stirring at an ambient temperature ranging from 10 to 80° C. and then homogenizing the mixture at a pressure ranging from 6×107Pa to 18×107Pa. 22. The process of claim 21, wherein said mixing is conducted at a shearing of 2×106s-1to 5×108s-1. 23. A method of caring for skin comprising applying the nanoemulsion according to claim 1 to the skin. 24. A method of treating skin comprising applying the nanoemulsion according to claim 1 to the skin. 25. A method of making up skin comprising applying the nanoemulsion according to claim 1 to the skin. 26. A method of caring for hair comprising applying the nanoemulsion according to claim 1 to the hair. 27. A method of treating hair comprising applying the nanoemulsion according to claim 1 to the hair.